Open AccessParathyroid Hormone-Related Protein for the Treatment of Postmenopausal Osteoporosis: Defining the Maximal Tolerable Dose
Author(s) -
Mara J. Horwitz,
Mary Beth Tedesco,
Adolfo Garcı́a-Ocaña,
Susan M. Sereika,
Linda Prebehala,
Alessandro Bisello,
Bruce W. Hollis,
Caren M. Gundberg,
Andrew F. Stewart
Publication year - 2010
Publication title -
the journal of clinical endocrinology and metabolism/journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2009-0233
Subject(s) - anabolism , medicine , endocrinology , bone resorption , parathyroid hormone , placebo , bone remodeling , osteoporosis , adverse effect , parathyroid hormone related protein , calcium , alternative medicine , pathology
PTH is the only approved skeletal anabolic agent for the treatment of human osteoporosis. Unlike PTH, which is a mixed anabolic and catabolic agent, PTHrP displays features suggesting that it may be a pure anabolic agent when intermittently administered. The full dose range of PTHrP is unknown.